

- Katz RT, Rovai G, Brait C, Rymer WZ. (1992) Objective quantification of spastic hypertonia: correlation with clinical findings. *Arch Phys Med Rehabil* **73**: 339–47.
- Lange DJ, Brin MF, Warner CL, Fahn S, Lovelace RE. (1987) Distant effects of local injection of botulinum toxin. *Muscle Nerve* **10**: 552–5.
- Montecucco C, Schiavo G. (1993) Tetanus and botulism neurotoxins: a new group of zinc proteases. *Trends Biochem Sci* **18**: 324–7.
- Picket AM, Hambleton P. (1994) Dose standardization of botulinum toxin. *Lancet* **344**: 474–5.
- Sanders DB, Massey EW, Buckley EG. (1986) Botulinum toxin for blepharospasm: single-fiber EMG studies. *Neurology* **36**: 545–7.
- Schiavo G, Rossetto O, Benfenati F, Poulain B, Montecucco C. (1994) Tetanus and botulinum neurotoxins are zinc proteases specific for components of the neuroexocytosis apparatus. *Ann New York Academy Sci* **710**: 65–75.
- Shaari CM, Sanders I. (1993) Quantifying how location and dose of botulinum toxin injections affect muscle paralysis. *Muscle Nerve* **16**: 964–9.
- Shin HI, Han TR, Seo KI. (2000) Effects of dilution volume of botulinum toxin A. *J Korean Acad Phys Med Rehabil* **28**: 67. (Abstract).
- Simpson DM, Alexander DN, O'Brien CF, Tagliati M, Aswad AS, Leon JM, Gibson J, Mordaunt JM, Monaghan EP. (1996) Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo controlled trial. *Neurology* **46**: 1306–10.
- Snow BJ, Tsui JK, Bhatt MH, Varelas M, Hashimoto SA, Calne DB. (1990) Treatment of spasticity with botulinum toxin: a double-blind study. *Ann Neurol* **28**: 512–5.
- Uniform Data System for Medical Rehabilitation. (1993) State University of New York at Buffalo, Version 4.0. (Functional Independence Measure Manual).
- Yablon SA, Agana BTX-A, Ivanhoe CB, Boake C. (1996) Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury: an open-labeled trial. *Neurology* **47**: 939–44.
- Zuber M, Sebald M, Bathien N, De Recondo J, Rondot P. (1993) Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. *Neurology* **43**: 1715–8.

Erratum

Hand function in children with hemiplegic cerebral palsy: prospective follow-up and functional outcome in adolescence
**Ermellina Fedrizzi, Emanuela Pagliano, Elena Andreucci,
Giovanna Oleari
DMCN 45: 85–91**

Owing to an error on our part, the Figure 2 legend in Fedrizzi et al.'s paper was printed incorrectly. Please see the figure legend labels below which have been corrected. We regret this error and give our apologies to the authors.
DOI: 10.1017/S0012162203000422




Figure 2: (a) Outcome of affected hand function in relation to initial grip impairment; (b) outcome of affected hand function in relation to initial impairment of bilateral manipulation.